<DOC>
	<DOCNO>NCT00006669</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way kill cancer cell . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness rituximab follow combination chemotherapy treat patient refractory recurrent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Followed Combination Chemotherapy Treating Patients With Refractory Recurrent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient refractory recurrent CD20+ intermediate grade B-cell non-Hodgkin 's lymphoma treat rituximab follow etoposide , vincristine , doxorubicin , cyclophosphamide , prednisone ( EPOCH ) . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive rituximab IV 4-10 hour day 1 follow etoposide , vincristine , doxorubicin IV continuously day 4-7 , cyclophosphamide IV 5-30 minute day 8 oral prednisone day 4-8 . Patients also receive sargramostim ( GM-CSF ) subcutaneously begin day 9 blood count recover . Treatment repeat every 21 day maximum 8 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis intermediate grade Bcell CD20+ nonHodgkin 's lymphoma Failed achieve initial complete response ( CR ) least 2 course standard chemotherapy OR Relapsed CR eligible autologous bone marrow transplant Measurable disease define one following : Bidimensionally measurable disease least 2 cm diameter radiograph CT scan Enlarged spleen extend least 2 cm costal due lymphomatous involvement Enlarged liver focal lesion CT scan biopsy proven lesion Lymphomatous hepatic involvement must biopsy proven liver sole area measurable disease No evidence CNS involvement A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3* Platelet count least 100,000/mm3* *unless bone marrow involvement lymphoma Hepatic : Bilirubin le 3 mg/dL AST/ALT le 2 time normal Renal : Creatinine le 2.1 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : LVEF great 45 % MUGA echocardiogram Other : No prior malignancy within past 10 year except squamous cell carcinoma basal cell carcinoma skin cervical cancer No evidence infection HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>